Clinical trial · Observational
Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC
Pyrotinib Combined With Trastuzumab and Chemotherapy in HER2-positive Metastatic Breast Cancer Patients- a Multicenter Retrospective Study
NCT04609540CI-TRIAL-00048848unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To explore the real world data of trastuzumab Combined With Trastuzumab And Chemotherapy in China, and to explore the relationship between progression free survival and treatment pattern.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HER2-positive Breast Cancer | HER2-Positive Breast Carcinoma | ALIAS | 0.90 |
| Metastatic Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Trastuzumab | Drug | Trastuzumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Pyrotinib and Trastuzumab group
- description
- Dual anti-HER2 therapy (pyrotinib and trastuzumab) and chemotherapy
- interventionNames
- Drug: Trastuzumab
Primary outcomes (1)
- measure
- Progression free survival(PFS)
- timeFrame
- 1 year
- description
- The time from starting pyrotinib until disease progression or death from any cause.
Secondary outcomes (3)
- measure
- Overall survival(OS)
- timeFrame
- 1 year
- description
- The time from starting pyrotinib until death, regardless of cause.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * woman, age \> 18 years old * Diagnosed with HER2 +Metastatic Breast Cancer * Pyrotinib Combined With Trastuzumab And Chemotherapy for at least one cycle, starting from 2020.11.01-2021.10.31 * Available medical history Exclusion Criteria: * Incomplete medical history
References
Publications (1)
- DERIVEDZhang L, Li C, Song S, Wang F, Ding T, Liu Z, Jin Y, Yu Z. A real-world comparison study of the efficacy of dual-target first-line rescue treatment of human epidermal growth factor receptor 2 positive advanced breast cancer: trastuzumab combined with pertuzumab versus trastuzumab combined with pyrotinib. Front Oncol. 2026 Mar 4;16:1720851. doi: 10.3389/fonc.2026.1720851. eCollection 2026. PMID 41858362